HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr Yuan on the Evolution of Radiation Therapy Approaches in Breast Cancer

September 17th 2024

Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.

Dr Tarantino on Advances Allowing for Tailored Treatment in HER2+ Breast Cancer

September 16th 2024

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Neoadjuvant Endocrine Therapy Plus Trastuzumab/Pertuzumab Yields Comparable Survival in HR+/HER2+ Early Breast Cancer

September 14th 2024

Neoadjuvant endocrine therapy or paclitaxel combined with trastuzumab and pertuzumab achieved notable survival benefits in HR-positive, HER2-positive early breast cancer.

TILs May Prognosticate Survival Benefit With Treatment De-escalation in Early HER2+ Breast Cancer

September 14th 2024

Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.

Dr Lin on the Efficacy of T-DXd in HER2+ Advanced Breast Cancer With CNS Metastases

September 14th 2024

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets

September 13th 2024

T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.

Nuances of HER2 Expression Underscore Need for More Precise Testing in Breast Cancer

September 11th 2024

As more therapies emerge for HER2-positive, -low, or -negative breast cancer, pathologists highlight the need for more precise methods of evaluating HER2 expression.

HER2DX Shows Correlation Between ERBB2 mRNA Levels and Survival in HER2+ Breast Cancer

September 10th 2024

HER2DX showed a strong association between ERBB2 mRNA score and survival outcomes in tumor samples from patients with advanced HER2-positive breast cancer.

Pyrotinib Plus Metronomic Vinorelbine Is Active in HER2+ Advanced Breast Cancer After Trastuzumab

September 5th 2024

Pyrotinib paired with metronomic vinorelbine was safe and displayed efficacy in HER2-positive advanced breast cancer after prior trastuzumab.

Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast Cancer

August 29th 2024

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

Shortened Trastuzumab Administration Does Not Improve DFS in ERBB2+ Breast Cancer

August 29th 2024

Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS outcomes when administered for 9 weeks vs 1 year in ERBB2-positive breast cancer.

Dr Forsyth on the Potential Utility of Intrathecal cDC1s in Leptomeningeal Disease

August 27th 2024

Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.

Dr Waks on Ongoing Research in Residual HER2+ Breast Cancer

August 23rd 2024

Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.

Dr O’Brien on Tucatinib Plus Trastuzumab/Capecitabine for Leptomeningeal Metastases in HER2+ Breast Cancer

August 22nd 2024

Barbara Jane O’Brien, MD, discusses tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases in HER2-positive breast cancer.

Dr Nanda on Treatment De-Escalation in HER2+ Breast Cancer and TNBC

August 22nd 2024

Rita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.

Dr Tolaney on Frontline Treatment Approaches in HER2+ Breast Cancer

August 20th 2024

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

EMA Accepts Marketing Application for T-DXd in HER2-Low and -Ultralow Metastatic Breast Cancer

August 19th 2024

The EMA has validated a type II variation application for trastuzumab deruxtecan for select patients with HER2-low or -ultralow metastatic breast cancer.

Dr Waks on Anthracycline- vs Taxane-Based Therapy in HER2+ Breast Cancer

August 13th 2024

Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer.

Novel Studies Seek to Optimize HER2+ Breast Cancer Management

August 7th 2024

Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer

August 6th 2024

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.